By Gina Shaw
On July 25, the FDA finalized long-awaited guidance for pharmaceutical companies about using electronic health record and medical claims data in the process of submitting drugs for approval. The final guidance updates a draft version released in September 2021.
“This guidance does not provide recommendations on choice of study design or type of statistical analysis,” the document noted, nor does it endorse any specific type or source of data. “This guidance is